Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Mar
27
Today In Oncology
AI As Collaborator in Cancer Research and in Clinical Care
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma
Gedatolisib-Based Regimens in HR-Positive HER2-Negative PIK3CA Wild-Type Advanced Breast Cancer
Hyperplasia and the Link Between Obesity and Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo